Search | IOVS | ARVO Journals

Showing 1 – 20 of 177

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

Immunology and Microbiology September 2024

Relationship Between Fluoroquinolone Resistance and Mutations in the Quinolone Resistance-Determining Region in Corynebacterium macginleyi

PDF

Nobuhiro Kato; Masatoshi Haruta; Rikki Arai; Kazunori Sato; Kei Furushima; Kanako Yokomizo; Miki Okuno; Takeshi Yamamoto; Yoshitoshi Ogura; Shigeo Yoshida
TAGS: corynebacterium, fluoroquinolones, mutation, quinolones, resistance genes, conjunctiva
Invest. Ophthalmol. Vis. Sci.. 2024; 65(11):38. https://doi.org/10.1167/iovs.65.11.38

ARVO Annual Meeting Abstract June 2024

OpRegen retinal pigment epithelial (RPE) cell therapy engrafts within the RPE of Gottingen mini-pigs by 4-weeks post-administration via subretinal delivery

Rachel Nicole Andrews; Henry E Wiley; Yuichiro Ogura; Amy Shelton; Tammy Tam; Ryan Boyd; Victoria Stevenson; Tracy Carlson; Colin Jennings; Kyle DePlancke; Vladimir Bantseev

Invest. Ophthalmol. Vis. Sci.. 2024; 65(7):5416.

ARVO Annual Meeting Abstract June 2021

Autologous iris pigment epithelial cell sheet implants for chorioretinal diseases with retinal pigment epithelial atrophy

Tsutomu Yasukawa; Yoshio Hirano; Aki Kato; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2021; 62(8):2695.

ARVO Annual Meeting Abstract July 2019

Psychological impact of treat-and-extend ranibizumab therapy in patients with age-related macular degeneration

SATOSHI KUWAYAMA; Aki Kato; Tsutomu Yasukawa; Iichiro Sugita; Munenori Yoshida; Miho Nozaki; Yoshio Hirano; Junko Kondo; Tomohiro Abe; Kimiko Sugita; Takahide Okita; Hiroshi Morita; Kazuhiko Sugitani; Naomi Inoue; Noriaki Takase; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):89.

ARVO Annual Meeting Abstract July 2019

Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for wet age-related macular degeneration with subretinal hyperreflective material

Ryoko Takeuchi; Tsutomu Yasukawa; Aki Kato; Tomohiro Obayashi; Satoshi Kuwayama; Soichiro Kuwayama; Norihiro Suzuki; Noriaki Takase; Naomi Inoue; Kazuhiko Sugitani; Yoshio Hirano; Munenori Yoshida; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):96.

ARVO Annual Meeting Abstract July 2019

Impacts of cataract surgery in eyes treated by anti-vascular endothelial growth factor therapy for wet age-related macular degeneration on visual outcomes

Tomohiro Obayashi; Tsutomu Yasukawa; Ryoko Takeuchi; Miho Inagaki; Katsuya Suzuki; Noriaki Takase; Naomi Inoue; Aki Kato; Hiroshi Morita; Yoshio Hirano; Miho Nozaki; Munenori Yoshida; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):97.

ARVO Annual Meeting Abstract July 2019

Long-term prognosis of eyes with tilted disc syndrome-associated serous retinal detachment

Soichiro Kuwayama; Fumihiro Kubota; Aki Kato; Fumi Gomi; Seiji Takagi; Takamasa Kinoshita; Hiroto Ishikawa; Yoshinori Mitamura; Mineo Kondo; Chiharu Iwahashi; Yasuo Kurimoto; Yuichiro Ogura; Tsutomu Yasukawa

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):6587.

ARVO Annual Meeting Abstract July 2019

Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER

Rishi P Singh; Charles Clifton Wykoff; Ramin Tadayoni; Yuichiro Ogura; Adrian H C Koh; Frank G Holz; Robin Hamilton; David Tanzer; Georges Weissgerber; Jahangir Alam; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5194.

ARVO Annual Meeting Abstract July 2019

Twenty-four month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study: visual prognosis and rate of complete resolution of macular edema

MIHO INAGAKI; Yoshio Hirano; Norihiro Suzuki; Yusuke Yasuda; Mihoko Kawamura; Tsutomu Yasukawa; Munenori Yoshida; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):4068.

ARVO Annual Meeting Abstract July 2018

Predictability of Progression of Diabetic Retinopathy by the Assessment of Foveal Avascular Zone with Optical Coherence Tomography Angiography

Katsuya Suzuki; Miho Nozaki; Noriaki Takase; Aki Kato; Hiroshi Morita; Hironori Ozeki; Munenori Yoshida; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3577.

ARVO Annual Meeting Abstract July 2018

Assessment of Mental Burden of Patients with Neovascular Age-Related Macular Degeneration Treated by Treat-and-Extend Regimen with Intravitreal Ranibizumab

Aki Kato; Tsutomu Yasukawa; Iichiro Sugita; Munenori Yoshida; Miho Nozaki; Yoshio Hirano; Junko Kondo; Tomohiro Abe; Kimiko Sugita; Takahide Okita; Hiroshi Morita; Kazuhiko Sugitani; Hideaki Usui; Naomi Niwa; Fusae Kato; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):800.

ARVO Annual Meeting Abstract July 2018

Genome-wide association study for response to ranibizumab therapy in 919 individuals with age-related macular degeneration

Masato Akiyama; Atsushi Takahashi; Yukihide Momozawa; Satoshi Arakawa; Fuyuki Miya; Yuji Oshima; Miho Yasuda; Shigeo Yoshida; Yasuo Yanagi; Koji Tanaka; Yuichiro Ogura; Kanji Takahashi; Kimihiko Fujisawa; Kazuaki Kadonosono; Tatsuro Ishibashi; Koh-hei Sonoda

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1426.

ARVO Annual Meeting Abstract July 2018

Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER

Pravin U Dugel; Gabriele Elisabeth Lang; Sam Razavi; Andreas Weichselberger; Yuichiro Ogura; David M Brown

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1455.

ARVO Annual Meeting Abstract July 2018

Analyses of data in Japanese Retina and Vitreous Society registry on eyes with rhegmatogenous retinal detachments

Takayuki Baba; Taiji Sakamoto; Ryo Kawasaki; Akito Hirakata; Shuichi Yamamoto; Koichi Nishitsuka; Takashi Koto; Keita Yamakiri; Kazuaki Kadonosono; Masahito Ohji; Hidetoshi Yamashita; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1834.

ARVO Annual Meeting Abstract July 2018

Superiority of ultra-wide field retinal imaging on detection of fundus abnormalities in the general medical checkup (human dock)

Takuma Maezawa; Hideaki Usui; Aki Kato; Noriaki Takase; Tsutomu Yasukawa; Yoshio Hirano; Miho Nozaki; Munenori Yoshida; Yuichiro Ogura

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4682.

ARVO Annual Meeting Abstract July 2018

2-Year Results of the PLANET Study: Intravitreal Aflibercept Alone and With Rescue Photodynamic Therapy in Polypoidal Choroidal Vasculopathy

Won Ki Lee; Yuichiro Ogura; Tomohiro Iida; Shih-Jen Chen; Tien Yin Wong; Paul Mitchell; Jeannie Qiu; Sergio Leal; Tatsuro Ishibashi

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):4949.

ARVO Annual Meeting Abstract July 2018

Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER

Glenn J Jaffe; Adrian H C Koh; Yuichiro Ogura; Andreas Weichselberger; Frank G. Holz; Pravin U Dugel

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):1624.

ARVO Annual Meeting Abstract June 2017

Efficacy and Safety of Intravitreal Aflibercept in Polypoidal Choroidal Vasculopathy: 12-Month Results of the PLANET Study

Won Ki Lee; Yuichiro Ogura; Tomohiro Iida; Shih-Jen Chen; Tien Yin Wong; Paul Mitchell; Tatsuro Ishibashi; eric zhang; Sergio Leal

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1199.

ARVO Annual Meeting Abstract June 2017

Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO

David M Brown; Yuichiro Ogura; Francesco Boscia; Frank G Holz; Jean-Francois Korobelnik; Jeffrey Heier; Kay D Rittenhouse; Friedrich Asmus; Christiane Ahlers; Florian Hiemeyer; Chengxing Lu; Robert Vitti; Namrata Saroj; Nicolas Feltgen

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1559.

Retina October 2016

Retinal Hemodynamics Seen on Optical Coherence Tomography Angiography Before and After Treatment of Retinal Vein Occlusion

PDF

Norihiro Suzuki; Yoshio Hirano; Taneto Tomiyasu; Yuya Esaki; Akiyoshi Uemura; Tsutomu Yasukawa; Munenori Yoshida; Yuichiro Ogura
TAGS: angiogram, eye, hemodynamics, optical coherence tomography, retinal vein occlusion, blood capillaries, nasopharyngeal aspirate
Invest. Ophthalmol. Vis. Sci.. 2016; 57(13):5681-5687. https://doi.org/10.1167/iovs-16-20648

1 2 3 4 5

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Relationship Between Fluoroquinolone Resistance and Mutations in the Quinolone Resistance-Determining Region in Corynebacterium macginleyi

OpRegen retinal pigment epithelial (RPE) cell therapy engrafts within the RPE of Gottingen mini-pigs by 4-weeks post-administration via subretinal delivery

Autologous iris pigment epithelial cell sheet implants for chorioretinal diseases with retinal pigment epithelial atrophy

Psychological impact of treat-and-extend ranibizumab therapy in patients with age-related macular degeneration

Combination therapy with intravitreal tissue plasminogen activator and ranibizumab for wet age-related macular degeneration with subretinal hyperreflective material

Impacts of cataract surgery in eyes treated by anti-vascular endothelial growth factor therapy for wet age-related macular degeneration on visual outcomes

Long-term prognosis of eyes with tilted disc syndrome-associated serous retinal detachment

Visual and expanded anatomical outcomes for brolucizumab versus aflibercept in patients with neovascular AMD: 96-week data from HAWK and HARRIER

Twenty-four month results of intravitreal ranibizumab for macular edema after branch retinal vein occlusion in a single-center prospective study: visual prognosis and rate of complete resolution of macular edema

Predictability of Progression of Diabetic Retinopathy by the Assessment of Foveal Avascular Zone with Optical Coherence Tomography Angiography

Assessment of Mental Burden of Patients with Neovascular Age-Related Macular Degeneration Treated by Treat-and-Extend Regimen with Intravitreal Ranibizumab

Genome-wide association study for response to ranibizumab therapy in 919 individuals with age-related macular degeneration

Predictability of the 12-week dosing status at Week 48 for patients receiving brolucizumab in HAWK and HARRIER

Analyses of data in Japanese Retina and Vitreous Society registry on eyes with rhegmatogenous retinal detachments

Superiority of ultra-wide field retinal imaging on detection of fundus abnormalities in the general medical checkup (human dock)

2-Year Results of the PLANET Study: Intravitreal Aflibercept Alone and With Rescue Photodynamic Therapy in Polypoidal Choroidal Vasculopathy

Phase III studies of brolucizumab versus aflibercept in nAMD: 48-week primary and key secondary outcomes from HAWK/HARRIER

Efficacy and Safety of Intravitreal Aflibercept in Polypoidal Choroidal Vasculopathy: 12-Month Results of the PLANET Study

Impact of baseline retinal nonperfusion on best corrected visual acuity in eyes with central retinal vein occlusion: post hoc analyses of COPERNICUS and GALILEO

Retinal Hemodynamics Seen on Optical Coherence Tomography Angiography Before and After Treatment of Retinal Vein Occlusion

To View More...

You must be signed into an individual account to use this feature.